NCT06885697 2026-02-17
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
Clinical Trials
7 trialsNCT04840615 2024-02-02
Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT00094978 2019-12-12
Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT01258868 2019-12-03
Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT03436732 2019-11-22
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT01445392 2018-08-03
SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT02567396 2017-04-24
Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
Phase 1 Withdrawn